Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax by Hockings, C. et al.
  
 
 
 
Hockings, C., Anwari, K., Ninnis, R. L., Brouwer, J., O'Hely, M., Evangelista, M., Hinds, M. G., Czabotar, P. 
E., Lee, E. F., Fairlie, W. D., Dewson, G. and Kluck, R. M. 2015, Bid chimeras indicate that most BH3-only 
proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax, Cell death and 
disease, vol. 6, pp. 1-8. 
 
DOI: 10.1038/cddis.2015.105 
 
 
 
 
 
This is the published version. 
 
©2015, Macmillan Publishers  
 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
 
 
 
 
 
 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30080429 
 
 
 
 
 
OPEN
Bid chimeras indicate that most BH3-only proteins can
directly activate Bak and Bax, and show no preference
for Bak versus Bax
C Hockings1,2, K Anwari1,2, RL Ninnis1,2, J Brouwer1,2, M O’Hely1,2, M Evangelista1,2, MG Hinds3,4, PE Czabotar1,2, EF Lee1,2,
WD Fairlie1,2, G Dewson1,2 and RM Kluck*,1,2
The mitochondrial pathway of apoptosis is initiated by Bcl-2 homology region 3 (BH3)-only members of the Bcl-2 protein family. On
upregulation or activation, certain BH3-only proteins can directly bind and activate Bak and Bax to induce conformation change,
oligomerization and pore formation in mitochondria. BH3-only proteins, with the exception of Bid, are intrinsically disordered and
therefore, functional studies often utilize peptides based on just their BH3 domains. However, these reagents do not possess the
hydrophobic membrane targeting domains found on the native BH3-only molecule. To generate each BH3-only protein as a
recombinant protein that could efficiently target mitochondria, we developed recombinant Bid chimeras in which the BH3 domain was
replaced with that of other BH3-only proteins (Bim, Puma, Noxa, Bad, Bmf, Bik and Hrk). The chimeras were stable following
purification, and each immunoprecipitated with full-length Bcl-xL according to the specificity reported for the related BH3 peptide.
When tested for activation of Bak and Bax in mitochondrial permeabilization assays, Bid chimeras were ~ 1000-fold more effective
than the related BH3 peptides. BH3 sequences from Bid and Bim were the strongest activators, followed by Puma, Hrk, Bmf and Bik,
while Bad and Noxa were not activators. Notably, chimeras and peptides showed no apparent preference for activating Bak or Bax. In
addition, within the BH3 domain, the h0 position recently found to be important for Bax activation, was important also for Bak
activation. Together, our data with full-length proteins indicate that most BH3-only proteins can directly activate both Bak and Bax.
Cell Death and Disease (2015) 6, e1735; doi:10.1038/cddis.2015.105; published online 23 April 2015
The Bcl-2 family of proteins controls the mitochondrial path-
way of apoptosis, a process often dysregulated in cancer and
other diseases.1–3 Apoptotic triggers including DNA damage
and oncogene activation cause the synthesis or activation of
one or more pro-apoptotic Bcl-2 homology region 3 (BH3)-only
proteins,1–4 a subfamily that includes Bid, Bim, Puma, Noxa,
Bad, Bik, Bmf and Hrk. These proteins then engage via their
BH3 domain with other Bcl-2 family members. BH3-only
proteins that can directly bind and activate the Bcl-2 effector
proteins Bak or Bax are called ‘activators’.5 When Bak or Bax
become activated and oligomerize in the mitochondrial outer
membrane (MOM), the apoptotic ‘switch’ has flipped and the
cell is committed to cell death. The prosurvival members (Bcl-
2, Bcl-xL, Mcl-1, Bcl-w, Bfl-1/A1 and Bcl-B) inhibit apoptosis by
specifically binding both the BH3-only proteins and activated
Bak and Bax.6–11 Thus, the cell’s complement of prosurvival
proteins, Bak, and Bax, determines the sensitivity of that cell to
each BH3-only protein, and by extension to each type of pro-
apoptotic stimulus.
A thorough understanding of BH3-only proteins is crucial for
the development of cancer therapeutics such as the new class
of anti-cancer molecules called BH3 mimetics that are
showing significant promise in clinical trials.12,13 The binding
of BH3-only proteins to prosurvival proteins has been well-
characterized and revealed significant preferences for enga-
ging different members.6,8,9 How BH3-only proteins bind and
activate Bak and Bax remains less understood for several
reasons. First, generating stable recombinant BH3-only
proteins is difficult because, except for Bid, they are
intrinsically disordered14–16 and because most contain hydro-
phobic C-terminal membrane anchors.17 Thus, most in vitro
studies of BH3-only proteins have used synthetic peptides
corresponding to the BH3 domains, C-terminally truncated
recombinant proteins or in vitro translated (IVT) proteins.
Second, BH3-only reagents bind poorly to recombinant Bak
and Bax in the absence of membranes, although detergents
and liposomes may substitute for the MOM.18–20 Third,
activation of Bak and Bax onmitochondria can be complicated
by the presence of other proteins such as prosurvival proteins.
Indeed, genetically altering BH3-only protein levels in mice
resulted in complex phenotypes due to multiple interactions
between family members, precluding firm conclusions as to
which BH3-only proteins are direct activators.18,21,22
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Bid and Bim are direct activators according to a variety of
approaches,5,8,9,23,24 and were recently proposed to be
specific for Bak and Bax, respectively.25 Early studies using
Noxa BH3 peptides5,8 and IVT Noxa9 concluded that Noxa
was not an activator. However, in more recent studies a Noxa
BH3 peptide23 and purified recombinant NoxaΔC20 were
found to be activators of both Bak and Bax. Puma has also
been described as both an activator26,27 and not an
activator.8,28 Du et al.23 analyzed the full panel of BH3
peptides and classified Bim as a strong activator, Bid, Noxa
and Bmf as moderate activators, and Puma, Bik and Hrk as
weak activators. The only BH3-only member that has never
been described as an activator is Bad.
While BH3 peptides and recombinant truncated BH3-only
proteins have been useful for in vitro studies, new reagents
that target mitochondria may better reflect the behavior of the
parent proteins. As Bid is stable as a recombinant protein, we
generated chimeras of Bid in which the BH3 domain of Bid was
replaced with that of seven other BH3-only proteins. This is a
similar approach to the Bim chimeras used for expression in
cells18 and in mice.29 More recently, truncated Bid (tBid)
chimeras containing the BH3 domains of Bim, Bak and Bax as
well as those of the prosurvival proteins, have been generated
as IVT proteins.11
To compare the ability of BH3-only proteins to activate Bak
and Bax in vitro, we incubated Bid chimeras and BH3 peptides
with mitochondria containing either Bak or Bax. We found that
the membrane-targeted Bid chimeras were much more potent
activators than their related BH3 peptides, and that all BH3
domains except for Bad and Noxa were activators to some
extent. We conclude that activation of Bak and Bax may be
underestimated by studies using BH3 peptides, and that even
BH3-only proteins such as Bik, Bmf and Hrk that are often
considered unable to activate Bak or Bax, may act as
activators under certain conditions.
Results
Bid BH3 chimeras are stable as recombinant proteins.
Bid is the only BH3-only protein that can be readily expressed
and purified as a recombinant protein. To generate stable
proteins that mimic the behavior of the other BH3-only
proteins the BH3 domain of human Bid (residues 81–100)
was replaced with the BH3 domains of 7 other human BH3-
only proteins to create the BidBim, BidPuma, BidNoxa, BidBad,
BidBik, BidBmf and BidHrk chimeras (Figure 1a). Bid chimeras
containing the BH3 domains of Bak and Bax were also
generated to explore Bak and Bax function, and to allow
comparison with the tBidBax and BidBak chimeras reported
previously.11 To simplify purification, the caspase-8 cleavage
site in Bid was replaced with a thrombin cleavage site,
allowing a combined cleavage/purification step.30 Thus, all
Bid chimeras presented in this study are ‘cleaved’ Bid (also
called n/cBid or p7/p15 Bid). A C-terminal haemagglutinin
(HA) tag was added to detect chimeras by immunoblotting,
and shown not to affect function (Supplementary Figure 1).
The swapped BH3 region was initially 20 residues covering
the 4 hydrophobic residues (h1–h4) important for binding to
prosurvival proteins31 and the 2 hydrophobic residues (h0)
recently shown to be important for binding to Bax.24 However,
four of the chimeras (those with Bim, Noxa, Bmf and Bak BH3
domains) expressed poorly or aggregated during purification
(not shown). This may be due to residues that correspond to
I83 in Bid (glutamate from Bim, Noxa and Bmf or methionine
from Bak, Supplementary Figure 2a) being poorly tolerated.
I83 normally makes contact with four hydrophobic residues in
helices 1 and 8 that may stabilize the protein (Supplementary
Figure 2b).32 Accordingly, when the swapped domain was
shortened to 16 residues to retain I83, the 4 chimeras were
stable (Figure 1b). As expected, the p15 fragments of all Bid
chimeras retained the ability to translocate to membranes of
mouse liver mitochondria (MLM) (Supplementary Figure 2c).
Bid BH3 chimeras exhibit specific binding to prosurvival
proteins. To evaluate the Bid BH3 chimeras, they were first
tested for binding to the Bcl-xL prosurvival protein (Figure 2a and
Supplementary Figure 3a). Equimolar chimera and full-length
Bcl-xL were incubated in the presence of Bak
− /− MLM, and the
immunoprecipitated Bcl-xL examined for bound chimera. Each
chimera, except for BidNoxa, co-precipitated strongly with Bcl-xL
(Figure 2a, upper panel), consistent with the binding of human
BH3 peptides to Bcl-xLΔC25 measured by surface plasmon
resonance (SPR) (Figure 2a, lower panel).6,7,10
C-terminally truncated prosurvival proteins have altered
BH3-binding specificity when tested on mitochondria.
When C-terminally truncated Bcl-xL (ΔC) was tested for
binding to Bid chimeras its specificity was significantly
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Figure 1 Bid BH3 chimeras are stable recombinant proteins. (a) Sequence of Bid
BH3 chimeras. Sequence alignment shows the Bid BH3 domain swapped for that of
other Bcl-2 family members. Hydrophobic residues (h1–h4) that are important for
binding to prosurvival proteins31 are highlighted, as are the recently identified h0
residues that are important for binding to Bax.24 (b) Recombinant Bid BH3 chimeras.
Chimeras were cleaved by thrombin during purification to generate N-terminal p7 and
C-terminal p15 fragments of Bid.30 Chimeras were separated by SDS-PAGE and
stained for total protein
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different to full-length Bcl-xL, with four chimeras (Bid
Bim,
BidBik, BidHrk and BidBax) showing little co-precipitation
(Figure 2b and Supplementary Figure 3a). Chimeras bound
to the canonical hydrophobic groove in full-length Bcl-xL,
rather than a site involving the C terminus, as the BH3
mimetic ABT-737 prevented co-precipitation (Supplementary
Figure 3b). Altered binding may be due in part to truncated
Bcl-xL remaining in the supernatant, whereas full-length
Bcl-xL (and Bid chimeras) was predominantly membrane
associated (Supplementary Figure 3c). Consequently, the
hydrophobic groove may adopt a different conformation and
therefore binding specificity on membrane insertion.
The chimeras also showed specific binding to truncated
Mcl-1 (ΔNΔC) and to truncated Bcl-2 (ΔC) (Figure 2b and
Supplementary Figure 3a). While binding was similar to that
of BH3 peptides on SPR, there were some exceptions.
For example, BidPuma bound poorly to Mcl-1ΔNΔC and BidBmf
bound poorly toBcl-2ΔC (Figure 2b). Thus,membrane insertion
may alter the binding profile of several prosurvival proteins.
In the absence of mitochondria, the chimeras immuno-
precipitated only weakly with truncated prosurvival proteins
(data not shown), consistent with the requirement of
membranes for separation of the Bid p7 and p15 fragments
and exposure of the Bid BH3 domain.33–35 Accordingly, SPR
(which is performed in the absence of membranes) also failed
to detect binding of the chimeras to Bcl-xLΔC and Mcl-1ΔNΔC
even in the presence of octyl glucoside (data not shown), a
detergent commonly used to separate the p7 and p15
fragments of Bid.36
In summary, binding of the chimeras to full-length Bcl-xL
(in the presence of mitochondria) reflected the specificity of
their cognate BH3 peptide. In addition, the importance of
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Figure 2 Bid BH3 chimeras show specific binding to prosurvival proteins. (a) Bid BH3 chimeras show specificity in binding to full-length Bcl-xL. Bid BH3 chimeras and full-
length Bcl-xL were incubated at a 1 : 1 molar ratio in the presence of Bak
− /− MLM before solubilization with 1% digitonin, immunoprecipitation (IP) of Bcl-xL and Western blotting
for bound chimera (HA tag). (b) Bid BH3 chimeras binding to truncated Bcl-xL, Mcl-1 and Bcl-2. The chimeras were incubated as in (a) with the indicated truncated prosurvival
proteins. Blots are representative of three independent experiments (shown in Supplementary Figure 3a). Bottom panels show previously published IC50 values of the equivalent
BH3 peptides for binding to truncated prosurvival proteins as measured by SPR.6,7,10
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studying full-length Bcl-2 proteins in their native environments
was highlighted by the altered binding specificity of Bid
chimeras to truncated prosurvival proteins.
Most BH3 chimeras and peptides activate Bak and Bax,
but with different potencies. To compare the ability of each
chimera or related BH3 peptide to activate Bak, wild-type
C57BL/6 MLM were incubated with increasing concentrations
of chimera or BH3 peptide and tested for cytochrome c
release. To test activation of Bax, MLM from Bak− /− mice
were supplemented with recombinant full-length Bax.37 MLM
have been used previously to assess Bak and Bax
activation11,24,38,39 as the remaining Bcl-2 proteins were
undetectable except for Bcl-xL which was present at low
levels (o3 nM).40 Cytochrome c release was used as a
measure of Bak or Bax activation as the two events correlated
strongly in wild-type MLM (Supplementary Figure 1), and no
cytochrome c release occurred in Bak− /− MLM without
addition of Bax (data not shown).5,40,41
Most Bid chimeras induced dose-dependent activation of
Bak (release of cytochrome c), allowing estimation of their
EC50 (Figure 3a). Similar experiments performed for Bak
activation by BH3 peptides, and for Bax activation by Bid
chimeras and peptides, allowed us to compare Bak and Bax
activation by both types of reagents (Figure 3b). Bid and BidBim
and the related peptides were strong activators of both Bak
and Bax (Figure 3b), consistent with previous reports.5,9,23
BidPuma chimera and Puma peptide were also activators, in
agreement with some9,23,26,27 but not other reports.8,28 Bmf,
Hrk and Bik reagents were activators, with Bik being the
weakest. While BidNoxa could also activate both Bak and Bax,
the Noxa peptide had no apparent activator activity. As BidBad
chimera and Bad peptide often failed to completely release
cytochrome c, the EC50 was not included in Figure 3b. The
Noxa and Bad results are discussed in more detail below.
Finally, BidBak and BidBax chimeras (and equivalent BH3
domain peptides) could activate both Bak and Bax, as
previously reported,11 and consistent with Bak and Bax being
able to auto-activate.42
By comparing both Bak and Bax activation by each chimera
and BH3 peptide, we could draw several conclusions. First,
the Bid chimeras were generally41000-fold more potent than
their related BH3 peptide in activating Bak. This was
attributable to the Bid scaffold targeting all chimeras to the
MOM (Supplementary Figure 2c), consistent with targeting a
Bid peptide to liposomes making it nearly as potent as the Bid
protein in activating Bax.43 The Bid scaffold may also increase
the affinity of the BH3 domain by stabilizing its structure, or by
aligning the BH3 domain to the activation site on Bak and Bax.
Second, the chimeras are reasonable mimics of their parent
BH3-only proteins, as the relative potency of each chimera,
with the exception of Noxa, reflected the relative potency of the
cognate BH3 peptide (Figure 3b). Third, the relative potencies
of the chimeras for activating Bak and Bax were similar, as
were the potencies of the peptides (Figure 3b and
Supplementary Figure 4). Thus, while BH3-only proteins
show specificity for certain prosurvival proteins, they may not
for Bak and Bax. In particular, in contrast to a recent report,25
there was little evidence of Bid preferentially targeting Bak and
Bim preferentially targeting Bax, as BidBim was approximately
fourfold less potent than Bid in activating both Bak and Bax.
Bad does not directly activate Bak or Bax, but can do so
indirectly. Compared with the other BH3-only reagents, the
BidBad chimera and Bad peptide caused a more graded and
often incomplete release of cytochrome c, particularly in the
Bax experiments (Figure 4 and Supplementary Figure 5).
This made EC50 estimations problematic, and suggested that
the Bad-like reagents caused cytochrome c release indirectly
(also called de-repression). As Noxa peptide, that does not
bind to Bcl-xL,
6 did not cause any cytochrome c release
(Figure 3b), it is possible that the Bad-like reagents bind
endogenous Bcl-xL present on MLM to liberate endogenous
activators that then activate Bak or Bax. Variable cytochrome
c release induced by Bad-like reagents (Supplementary
Figure 5) might be explained by variation in the levels
of Bcl-xL and/or direct activators between mitochondria
preparations.
To further test direct activation by the chimeras, they were
tested for their ability to activate His-tagged BakΔCTon nickel-
chelating liposomes (Figure 5), as described previously.44
While the dose range (from 1 to 3 nM) was more limited in this
assay to avoid non-specific permeabilization, each chimera
except for BidBad was able to activate Bak and permeabilize
the liposomes. Moreover, the activation profile matched that
for full-length Bak in MLM (Figures 3a and b), indicating that
other Bcl-2 family proteins in MLM probably had little impact on
cytochrome c release by all chimeras except BidBad.
Noxa does not directly activate Bak or Bax. The finding
that BidNoxa, but not Noxa peptide, could activate Bak and
Bax (Figure 3) prompted us to test a recombinant variant of
the Noxa protein (Figure 6a). GST-NoxaΔC contains GST at
the N-terminus for increased stability and lacks the C-terminal
membrane anchor, similar to a variant of Noxa (S peptide-
NoxaΔC) reported to bind and activate BakΔC in liposomes.20
In the MLM, even very high concentrations (10 μM) of GST-
NoxaΔC did not activate Bak or Bax (Figure 6a) despite the
Noxa BH3 domain being available for binding to Mcl-1
(Figure 6b).
The Bid h0 contributes to Bak and Bax activation.
Mutagenesis was then used to examine why the BidNoxa
chimera activated Bak and Bax, but Noxa peptide and GST-
NoxaΔC did not (Figures 3b and 6a). As noted above, the
chimera contains the Bid sequence (QEDIIR) around the h0
region recently found to be important for activating Bax.24 To
test whether the h0 region might also contribute to Bak
activation, and account for the activator activity of BidNoxa,
we replaced the two h0 residues in BidNoxa with alanine,
flanked by residues from Bid (BidNoxah0AA1) or from Noxa
(BidNoxah0AA2) (Figure 6c). Activation of both Bak and Bax
was decreased by ~10-fold (Figure 6d), indicating that h0
residues contribute to activation of Bak as well as Bax. In the
reverse approach, we attempted to convert the Noxa peptide
to an activator by adding Bid sequence (Figure 6c). Introdu-
cing just the two h0 isoleucines of Bid (Noxa h0II peptide)
was not sufficient, but introducing seven Bid residues
(BidNoxa peptide) to mimic the swap in the BidNoxa chimera
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Figure 3 Bid chimeras and BH3 peptides are similar in their specificity for activating both Bak and Bax. (a) Bid chimeras activate Bak to release cytochrome c. Wild-type MLM
were treated with the indicated Bid chimeras and supernatant (sup) and pellet (pel) fractions Western blotted for cytochrome c (top panels). Quantification of cytochrome c release
allowed estimation of EC50 (bottom panels). (b) Comparison of Bak and Bax activation by Bid chimeras and BH3 peptides. Wild-type MLM (Bak activation) or Bak
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now converted the peptide to an activator (Figure 6e). Within
those seven Bid residues, the h0 residues were required as
their substitution with alanine (BidNoxa h0AA peptide)
abrogated Bak activation (Figure 6e). Residues flanking h0
may also promote or hinder activation, as BidNoxa peptide
but not Noxa h0II peptide could activate Bak and Bax
(Figure 6e) and the BidNoxa h0AA1 and hOAA2 mutant
chimeras did not lose all activator function (Figure 6d).
Results with the Noxa peptide are consistent with reduced
Bak activation by a Bid peptide in which truncation had
removed the h0 region.39 In summary, these experiments
show that h0 in both peptide and chimera can contribute to
Bak activation, as well as Bax activation.24
Discussion
The Bid chimeras were generally 41000 times more potent
than BH3 peptides at directly activating Bax/Bak (Figure 3), as
previously shown for Bid protein versus Bid BH3 peptide.8,43
The potency of the chimeras may be largely due to membrane
targeting by the Bid scaffold, as targeting a Bid peptide to
mitochondria rendered it almost as potent as Bid protein;43,45
induced helicity of the BH3 domain46,47 or improved ‘presenta-
tion’ of the BH3 domain toBak or Baxmayalso contribute. As all
BH3-only proteins (except Bad) contain a C-terminal
mitochondrial targeting domain,17 they are better represented
by the Bid chimeras than by BH3 peptides. In addition, as tBid
(the p15 fragment) becomes intrinsically disordered when
bound to membranes,48–51 the final tertiary structures of
chimeras and parent BH3-only proteins may be similar. Thus,
previous studies with BH3 peptides or truncated BH3-only
proteinsmay have underestimated the ability of the parent BH3-
only proteins to activate Bak and Bax, and the Bid chimeras
provide an improved means of assessing direct activation.
Our studies indicate that each of the BH3-only proteins,
except for Bad and Noxa, have some ability to activate Bak
and Bax. Bik, Bmf and Hrk are often considered to be
‘sensitizers’ that function only by binding and sequestering
prosurvival proteins. However, as our data indicate that they
may also activate Bak and Bax, both functions may be
important, as deduced for Bim in vivo.29
Our comparison of Bak and Bax showed that both were
activated by the same chimeras, and by the same peptides
(Figure 3 and Supplementary Figure 4). This is consistent with
liposome studies in which BakΔNΔC and Bax were activated
by the same BH3 peptides.23 Our findings differ from
experiments with permeabilized cells (which may contain
prosurvival proteins), where Bak was preferentially activated
by Bid, while Bax was preferentially activated by Bim.25 Our
findings are more consistent with their experiments with
isolated mitochondria and liposomes where the preference
was less apparent.25 Finally, the lack of specificity of BH3-only
proteins for activating Bak versus Bax, and a role for h0 in
activating both Bak and Bax, suggests similar activation sites
on both pore-forming proteins. Accordingly, several structures
show BH3 peptides bound to the canonical hydrophobic
grooves in Bak and Bax.24,39,52
In conclusion, cells have various means of activating Bak
and Bax, as most BH3-only proteins can directly activate Bak
and Bax, and others (Bad and Noxa) may indirectly activate
the two proteins. Direct activation is greatly enhanced by
targeting to mitochondria, suggesting that studies relying on
C-terminally truncated BH3-only proteins and BH3 peptides
underestimate direct activation by their parent BH3-proteins.
The Bid chimeras developed in this study are targeted to
membranes to better represent the interactions between
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BH3-only proteins and Bak and Bax that require a
membrane.17,33,43 Therefore, they are important new tools
for in vitro studies of Bcl-2 proteins on liposomes, vesicles or
mitochondria.
Materials and Methods
Generating recombinant proteins and BH3 peptides. Chimeras of
human Bid in which the BH3 domain (aa 81–100) was swapped with 20 residues
(human Puma 132–151, Bad 105–124, Bik 52–71, Hrk 28–47 and Bax 52–71) or 16
residues (Bid 85–100 replaced with human Bim 147–162, Noxa 24–39, Bmf 170–
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185 and Bak 73–88) by PCR site-directed mutagenesis. The Bid backbone had a
thrombin cleavage site in place of the caspase 8 cleavage site to allow one-step
cleavage and purification30 and was cloned into pGEX-4T2 to add a C-terminal HA
tag. Protein was expressed in Escherichia coli BL21 (DE3) induced with 1 mM
Isopropyl β-D-1-thiogalactopyranoside (IPTG) overnight at 18 °C. Bacteria
were lysed in lysis buffer (phosphate buffered saline with 1 mM EDTA, 10 μg/ml
aprotinin and 10 μg/ml leupeptin), with 1 mM dithiothreitol (DTT), 0.5 mM
phenylmethanesulfonyl fluoride, 266 μg/ml lysozyme and 37 μg/ml DNase I with a
homogenizer (EmulsiFlex, Avestin, Ottawa, ON, Canada). The lysate was
centrifuged and filtered, before incubation with glutathione beads (GE Healthcare
Bio-Sciences AB, Uppsala, Sweden). Washed beads were incubated overnight at
4 °C with thrombin in 50 mM Tris pH 8.0, 150 mM NaCl and 5 mM MgCl2. Eluate
was further purified by gel filtration (Superdex 75, GE Healthcare Bio-Sciences AB)
in Tris buffered saline (TBS; 20 mM Tris pH 8.0 and 150 mM NaCl) with 2 mM DTT.
Fractions were aliquoted and stored at − 80 °C.
Recombinant full-length human Bcl-xL was cloned into PTYB1 vector to produce a
fusion of Bcl-xL with an intein/chitin binding protein, which can be removed to obtain Bcl-
xL with vector encoded residues Gly–Ser–Ser at the C terminus. Protein was expressed
in ER2566 E. coli (New England Biolabs, Ipswich, MA, USA) induced with 0.5 mM IPTG
overnight at 18 °C. Bacteria were lysed with a homogenizer in TEN buffer (20 mM Tris
pH 8.0, 1 mM EDTA, 500 mMNaCl) with 10 mMMgCl2, 25 μg/ml DNase I and protease
inhibitor cocktail (Roche, Basel, Switzerland). CHAPS (1%, Sigma-Aldrich, St Louis,
MO, USA) was incubated with lysate for 30 min prior to centrifugation and filtration.
Clarified lysate was passed through a column with chitin resin, which was then washed
thoroughly with 0.2% CHAPS in TEN buffer. On-column cleavage of the intein tag was
induced with 50 mM DTT for at least 40 h at 4 °C. Bcl-xL was eluted and further purified
by gel filtration (Superdex 200) in TBS. Fractions were concentrated, aliquots flash
frozen with liquid nitrogen and stored at − 80 °C. BakΔC22-HexHis was produced by
the Bax purification protocol described previously.24 The expression and purification of
human Bax, mouse Mcl-1ΔN151ΔC23, human Bcl-xLΔC25 and human Bcl-2ΔC22
has been described previously.6,24
Human Noxa (residue 1–40) was cloned into pGEX 6P3 vector resulting in a
C-terminal GST tag. Protein was expressed in E. coli BL21 (DE3) induced with 1 mM
IPTG for 3 h at 37 °C. Bacteria were homogenized in TBS-E (TBS with 1 mM EDTA).
The lysate was centrifuged and filtered before passing through a GST column. The
column was then washed with TBS-E and bound proteins eluted with 10 mM reduced
glutathione (in TBS-E) then further purified by gel filtration (Superdex 75) in TBS.
Synthetic peptides based on human BH3 sequences were synthesized by
Mimotopes (Notting Hill, VIC, Australia) and purified by reverse-phase HPLC to
490% purity. Full peptide sequences are shown in Supplementary Figure 2. Most
peptides have been published previously: Bid (34-mer) in Willis et al.18 Bim, Noxa,
Bad and Hrk in Chen et al.6 Bak and Bax in Czabotar et al.24 Noxa mutant peptide
sequences are shown in Figure 5c.
Mitochondrial cytochrome c release. MLM were prepared from C57BL/6
wild-type or Bak− /− mice as described.53 MLM were diluted to 1 mg/ml in MELB
(100 mM KCl, 2.5 mM MgCl2, 100 mM sucrose, 20 mM HEPES/KOH pH 7.5, 5 mM
DTT) supplemented with protease inhibitor cocktail and 4 mg/ml pepstatin A (Sigma-
Aldrich). Recombinant full-length Bax, Bid BH3 chimeras, GST-NoxaΔC and BH3
peptides were added as indicated, and samples incubated for 2 h at 37 °C. When
chimeras were diluted significantly (e.g., dose–response experiments in Figures 3–5),
binding of protein to tubes was minimized by the presence of 1% BSA in diluent (final
0.01 to 0.03% BSA). Similarly, peptides were diluted in 100% DMSO (final 1–3% DMSO
on). Supernatant and pellet fractions were separated by centrifugation and analyzed by
sodium dodecyl sulfate (SDS)-PAGE and Western blotting for cytochrome c.
SDS-PAGE and Western blotting. SDS-PAGE and Western blotting was
performed as described.54 Primary antibodies used were anti-cytochrome c 7H8.2C12
mouse monoclonal (BD Biosciences, San Jose, CA, USA), anti-HA 16B12 mouse
monoclonal (Covance, Princeton, NJ, USA) or 3F10 rat monoclonal (Roche), anti-Mcl-1
19C4-15 rat monoclonal (WEHI mAb Facility, Bundoora, VIC, Australia55), anti-Bcl-x
rabbit polyclonal (BD Biosciences), anti-Bcl-2 Bcl-2-100 mouse monoclonal (WEHI
mAb Facility56), anti-Noxa 114C307 mouse monoclonal (Novus Biologicals, Littleton,
CO, USA) and anti-Bak 4B5 rat monoclonal (WEHI mAb Facility57). Secondary
antibodies were horseradish peroxidase-conjugated goat anti-mouse, goat anti-rabbit
and goat anti-rat (Southern Biotech, Birmingham, AL, USA).
Quantitation of cytochrome c release and dose–response
analysis. Western blot images were quantitated by densitometry with ImageLab
4.1 software (Bio-Rad, Hercules, CA, USA). Percentage cytochrome c release was
determined independently from the supernatant and pellet densitometry (using Excel
for Mac, Microsoft, Redmond, WA, USA) as follows. Percentage release in
supernatant was calculated as the ratio of each density to the maximum density in the
supernatant blot. The same calculation for pellet blots gave the percentage of
cytochrome c retained; percent release is then obtained by subtracting from 100%. In
cases where the densitometry on the pellet did not drop to zero (i.e., 100%
cytochrome c is not released) the supernatant percentages for that case were
multiplied by densities of sup/(sup+pellet) for the dose corresponding to maximum
cytochrome c release. The two measures of cytochrome c release (from supernatant
and pellet) were imported into Prism 6 (Graphpad, La Jolla, CA, USA) and treated as
two independent measures. Curves were fitted to the data using ‘log(agonist) versus
response’ non-linear regression. ‘Top’ and ‘Bottom’ values were fixed at the average
minimum and average maximum, respectively, of all blots in that experiment, and the
log(EC50) and Hill Slope parameters were unconstrained.
Immunoprecipitation. For immunoprecipitation of Bid BH3 chimeras with
prosurvival Bcl-2 proteins, 40 nM Bid chimeras were incubated with 40 nM hBcl-xL,
hBcl-xLΔC25, mMcl-1ΔN151ΔC23 or hBcl-2ΔC22 in the presence of 1 mg/ml
Bak− /− MLM. After 1 h at 37 °C, samples were solubilized with 1% digitonin and
immunoprecipitated as described57 using anti-Mcl-1 14C11 rat monoclonal,58 anti-
Bcl-xL IC2 rat monoclonal
7 or anti-Bcl-2 Bcl-2-100 mouse monoclonal antibodies
and Protein G Sepharose 4 fast flow (GE Healthcare Bio-Sciences AB).
Liposome permeabilization assay. Bak-mediated liposome assays were
based on previously described methods.44 Liposomes were prepared by drying lipid
mixes (46% phosphatidylcholine, 25% phosphatidylethanolamine, 11% phosphati-
dylinositol, 10% phosphatidylserine, 8% cardiolipin and 10% 18:1 DGS-NTA(Ni) 1,2-
dioleoyl-sn-glycero-3-[(N-(5-amino-1 carboxypentyl) iminodiacetic acid)succinyl]
(nickel salt)) in chloroform and 0.01% butylated hydroxytoluene under N2, and
then resuspending in liposome buffer (10 mM HEPES pH 7.5 and 135 mM KCl)
containing 50 mM 5(6)-carboxy-fluorescein. To remove excess free lipid and collect
a uniform size liposome mixture the sample was passed over a polycarbonate
membrane filter (diameter 19 mm; pore size 0.1 μm). To remove unincorporated
dye, the liposomes were passed through a PD10 desalting column. For each assay,
liposomes were used at a final concentration of 2.5 mM and the fluorescence of
released self-quenching 5(6)-carboxy-fluorescein measured at an excitation
wavelength of 485 nm and emission wavelength of 535 nm.
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